A clinical trial to evaluate the combination of a new drug called KPG-121 with abiraterone acetate (Zytiga) for treating metastatic castration-resistant prostate cancer (mCRPC) as a first-line therapy has been approved by the FDA.
KPG-121 is an investigational drug that targets specific proteins involved in prostate cancer cell growth and survival.
An earlier phase 1 study (NCT03569280) evaluated KPG-121 and showed a favorable safety profile and promising early signs of efficacy, with a 37.5% objective response rate (ORR).
Two years of abiraterone, monthly then quarterly Lupron injections, a full month of targeted radiation for bone metastases in pelvic region, age 75.8 now free of all treatments, regular PSApetscans, blood work, oncology visits to monitor. Side effects of injections and daily abiraterone were massive fatigue, hot flashes, helped me with two gabapentin per day. I fell great now, but recognize cancer still lurks in prostate, but quality of life immeasurably improved...cannot attribute it to any single treatment. Triple whammy
You sure were/are fermented. You'll be 76 soon and then you can change your ID to Sauerkraut. We all feel great hat you feel great. You're correct about Ca lurking in your body. My theory is that we all are born with Ca and it just takes "a this or a that" to trigger it. So just enjoy your freedom but keep your eye out for symptoms when you reach 96.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Abiraterone/enzalutamide+PARP inhibitor better than abiraterone/enzalutamide alone for mCRPC, even without BRCA+
Lu177 Phase 3 to FDA approval - how long usually
